CMS Reports: Cost-Effectiveness of Screening Tests for Colorectal Cancer
These efforts were undertaken as a joint effort between multiple CISNET groups and US Government health policy makers which resulted in two reports to Centers for Medicare and Medicaid Services (CMS). One is a cost effectiveness analysis for the new stool DNA test, completed in 2007. The other report is a cost effectiveness analysis for the new immunochemical fecal occult blood tests (FOBT), completed in 2003.
Cost-Effectiveness of DNA Stool Testing to Screen for Colorectal Cancer
CISNET members from Harvard School of Public Health, Sloan-Kettering, and Erasmus University worked together on the following report.
Zauber AG, Lansdorp-Vogelaar I, Wilschut J, Knudsen AB, van Ballegooijen M, Kuntz KM. Cost-effectiveness of DNA stool testing to screen for colorectal cancer: Report to AHRQ and CMS
from the Cancer Intervention and Surveillance Modeling Network (CISNET)
for MISCAN and SimCRC Models. December 20, 2007.Abailable from: https://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=52
Cost-Effectiveness of the Immunochemical Fecal Occult Blood Tests
CISNET members from Erasmus University and Memorial Sloan-Kettering worked together with NCI on the following report.
van Ballegooijen M, Habbema JDF, Boer R, Zauber AG, Brown ML. Report to the Agency for Healthcare Research and Quality: a comparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. August, 2003. Available from: http://www.cms.hhs.gov/mcd/viewtechassess.asp?where=index&tid=20
|
